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Abstract
Objective—Recently we demonstrated that scavenger receptor type BI (SR-BI), a HDL receptor,
was expressed on murine hematopoietic stem/progenitor cells (HSPC) and infusion of
reconstituted HDL and purified human apoA-I suppressed HSPC proliferation. We hypothesized
that SR-B1 expression is required for the observed anti-proliferative effects of HDL on HSPC.
Approach and Results—SR-BI deficient (SR-BI−/−) mice and wild type (WT) controls were
fed on chow or HFD (HFD) for 8–10 weeks. Under chow diet, a significant increase in Lin-
Sca1+cKit+ cells (LSK cells, so called HSPC) was found in the BM of SR-BI−/− mice compared
with WT mice. HFD induced a further expansion of CD150+CD48− LSK cells (HSCs), HSPCs,
and granulocyte monocyte progenitors (GMPs) in SR-BI−/− mice. Injection of reactive oxygen
species (ROS) inhibitor N-acetylcysteine attenuated HFD-induced HSPC expansion, leukocytosis
and atherosclerosis in SR-BI−/− mice. ApoA-I infusion inhibited HSPC cell proliferation, Akt
phosphorylation and ROS production in HSPC and plaque progression in low density lipoprotein
receptor knockout (LDLr−/−) apoA-I−/− mice on HFD but had no effect on SR-BI−/− mice on HFD.
Transplantation of SR-BI−/− BM cells into irradiated LDLr−/− recipients resulted in enhanced
white blood cells (WBC) reconstitution, inflammatory cell production and plaque development. In
patients with coronary heart disease, HDL levels were negatively correlated with WBC count and
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HSPC frequency in the peripheral blood. By flow cytometry, SR-BI expression was detected on
human HSPC.
Conclusions—SR-BI plays a critical role in the HDL-mediated regulation HSPC proliferation
and differentiation which is associated with atherosclerosis progression.
Key points
HDL; hematopoietic stem/progenitor cells; atherosclerosis
Introduction
High density lipoprotein (HDL) and its major component, apolipoprotein A-I (apoA-I), are
negatively correlated with the incidence of coronary heart disease.1 Recently, Yves-Charvet
et al., and our group demonstrated that infusion of reconstituted HDL (rHDL) or lipid poor
human apoA-I inhibits hematopoietic stem/progenitor cells (HSPCs) proliferation in
hypercholesterolemic Abca1−/− Abcg1−/− mice and C57BL/6 mice, therefore, limiting white
blood cell expansion in the peripheral blood (PB).2, 3 In addition, we demonstrated that the
HDL receptor, scavenger receptor type BI (SR-BI), is expressed on murine Lin-Sca-1+cKit+
(LSK cells, so called HSPC cells),3 which led to the hypothesis that HDL and apoA-I may
regulate HSPCs by binding to SR-BI.
HSPCs, responsible for all blood cell generation, reside in a hypoxic bone marrow (BM)
niche4, 5 and are largely quiescent. In general, HSPC are defined as Lin-Sca-1+cKit+ (LSK)
cells that include both hematopoietic stem and progenitor cells. Within HSPC, the most
primitive subpopulation that is capable of repopulating the hematopoietic system is named
long term hematopoietic stem cells (LT-HSCs, defined as CD150+CD48-LSK cells). HSCs
give rise to multiple progenitor cells (CD150-CD48-MPPs), a mature subset of HSPC, that
sequentially generate progenitors, lineage restricted precursors and finally all blood cells.
Therefore, LSK cells are widely used in studying HSPC. The potential for self-renewal,
proliferation and differentiation of HSPCs is finely balanced by different intrinsic and
extrinsic signals, which guarantee the continuous blood supply throughout life. Extrinsic
factors, such as cytokines, chemokines, growth factors and extracellular matrix molecules
bind to receptors on HSPCs, which then activate downstream signaling pathways, such as
phosphoinositide 3-kinase/AKT and MAPK signaling molecules, which regulate cell
survival vs. apoptosis, or self-renewal vs. differentiation. The Akt family of serine threonine
kinases are activated by phosphorylation of phosphoinositide 3-kinase. Although Akt1−/− or
Akt2−/− mice have only mild defects in hematopoiesis, HSPC function, including
proliferation and reconstitution capacities, is severely affected in Akt1−/− Akt2−/− mice,
suggesting an essential role of Akt in HSPC biology.6, 7 MAPKs are also a family of serine
threonine kinases consisting of ERKs, JNKs, and p38MAPKs.8–10 The role of ERKs in
HSPC proliferation differentiation and survival is well established, as are the roles of JNKs
on erythropoiesis, and p38MPAK activation in the regulation of erythropoiesis and myeloid
differentiation. 11
Aside from phospho Akt (pAkt) and MAPK, another group of molecules that critically
regulates HSPC proliferation and differentiation are reactive oxygen species (ROS).12, 13
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The hypoxic BM microenvironment is responsible for low ROS production in HSPCs,
which is important for the maintenance of HSPC quiescence and self-renewal, but not
differentiation.11 Comparison between ROShigh HSPCs and ROSlow HSPCs showed that the
ROSlow population represents the quiescent HSPC population with self-renew potential,
whereas the ROShigh HSPC subpopulation is activated, undergoes differentiation and then
exhaustion.12, 13 Moreover, pAkt acts upstream of ROS production,6 whereas, p38MAPK
activation is downstream of ROS production in HSPCs. 11
SR-BI, the HDL receptor, is expressed on hepatocytes and facilitates selective cholesterol
ester uptake from HDL. In addition, SR-BI also mediates LDL and VLDL clearance.14
Others and we have illustrated the anti-atherosclerotic function of SR-BI in different mouse
models.15–18 Different from mice, SR-BI deficiency in humans leads to multiple
pathophysiological phenotypes.19, 20 In mice, SR-BI deficiency is associated with impaired
HDL function, intracellular cholesterol accumulation and increased oxidative stress.21 We
previously demonstrated that SR-BI is expressed on murine HSPC.3 This led us to
hypothesize that SR-BI deficiency impairs cholesterol homeostasis, modulates Akt and
MAPK phosphorylation and leads to increased ROS production in HSPC, resulting in
enhanced HSPC proliferation and differentiation.
We here demonstrate a significant increase in LT-HSC, HSPCs and granulocyte monocyte
progenitors (GMP) in the BM of SR-BI−/− mice compared with WT mice on high fat diet
(HFD). Infusion of human apoA-I reduced HSPCs proliferation, Akt phosphorylation and
ROS production in HSPCs and inhibited plaque progression in LDLr−/− apoA-I−/− mice on
HFD but not in SR-BI−/− mice on HFD. Third, transplantation of SR-BI−/− BM cells into
irradiated LDLr−/− recipients resulted in enhanced white blood cell reconstitution,
inflammatory cell production and plaque development. Fourth, ROS inhibitor treatment
reversed leukocytosis and the increased LT-HSC and HSPC frequency and attenuated
atherosclerosis progression in SR-BI−/− mice induced by HFD. Finally we tested SR-BI
expression on human HSPC and assessed the effect of HDL levels on WBC count as well as
HSPC frequency in the blood. As we found in murine models, SR-BI is expressed on human
HSPC. In patients with coronary heart disease, HDL levels were negatively correlated with
WBC and HSPC frequency in the blood.
Materials and Methods
Human studies
Patients with coronary heart disease were enrolled in this study. Mononuclear cells in the PB
(PBMNC) were isolated by Ficoll (GE Heslthcare, Belgium) and stained with an anti-human
Lineage cocktail APC (BD), anti-human CD38 APC (eBioscience), anti-human CD34PE
(BD) and anti-human CD45RA PerCP-Cy5.5 (eBioscience). The frequency of HSPCs (Lin−
CD34+ CD38− CD45RA−/low cells) was determined on a Gallios apparatus (Beckman
Coulter).
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Murine studies
SR-BI−/− mice and control littermates were fed on HFD (34% fat, 1% cholesterol, Catalog
no. D12492 mod, BioServices, the Netherlands) or chow diet for 8–10 weeks. For apoA-I
studies, SR-BI−/− and SR-BI+/+ mice, or LDLr−/− apoA-I−/− (DKO) mice, fed with HFD for
11 and 9 weeks respectively, received during the last 3 weeks subcutaneous saline or lipid-
free human apoA-I injection (500 μg per injection, 2 injections per week).22 For ROS
inhibitor experiments, SR-BI+/+ and SR-BI−/− mice were fed with a HFD and received i.p.
injection of saline or N-acetylcysteine (NAC, Sigma-Aldrich, 1 mg/kg, daily) for 12 weeks.
Detailed methods are shown in the online-only Data Supplement.
Results
High fat diet induces leukocytosis, monocytosis, GMP, HSPC and LT-HSC expansion and
early onset of atherosclerosis SR-BI−/− mice
We have previously demonstrated that SR-BI, a HDL receptor, is expressed on murine
HSPCs.3 As infusion of rHDL or lipid poor human apoA-I inhibits HSPC proliferation in
hypercholesterolemic Abca1−/− Abcg1−/− mice and C57BL/6 mice,2, 3 we here investigated
if and how SR-BI might be involved in these effects. Eight week-old SR-BI−/− and SR-BI+/+
mice were fed on chow or high fat diet (HFD) (1% cholesterol, 34% fat) for 8–10 weeks.
The lipoprotein profiles are shown in supplementary figure I. HFD induced leukocytosis,
monocytosis and increased the number of F4/80+ macrophages in the PB of SR-BI−/− mice
compared to WT mice on HFD (Figure 1, A–C). In addition, we found more extensive
atherosclerotic plaques in the aortic roots in SR-BI−/− compared to WT mice (24517 ±
10625.1 μm2 vs. 6489 ± 1881.3 μm2, n=7 for each, P<0.001).
To address the role of SR-BI in the effects of HDL on HSPC, we enumerated the frequency
of LT-HSC cells (briefly, HSC), LSK cells (HSPC) and granulocyte monocyte progenitors
(GMP; CD34+ FcR+ lin− Sca-1− ckit+) in BM of SR-BI−/− and SR-BI+/+ mice on chow and
HFD. In animals maintained on chow diet, we found a 1.7-fold increase of the percentage of
LSK cells in the BM of SR-BI−/− mice compared with WT controls (LSK%: 0.090% vs.
0.054%; P<0.05; n=8–10). Following HFD, both HSC and LSK frequency was increased in
BM of SR-BI−/− compared to WT mice (HSC%: 0.014% vs. 0.009% at 8 weeks of HFD;
0.017% vs. 0.011% at 10 weeks of HFD; n=11 for each, P <0.01; LSK%: 0.135% vs.
0.095% at 8 weeks of HFD; 0.184% vs. 0.090%, n=11 for each, P <0.01) (Figure 1, D–E
and Supplementary figure II and VI). Although no difference was seen when mice were
maintained on chow diet, the percentage of GMPs in BM cells was 1.2- and 1.5- fold
increase in SR-BI−/− mice on HFD after 8 and 10 weeks of HFD, compared to WT mice on
HFD (GMP%: 0.633% vs. 0.530% at 8 weeks of HFD; 0.816% vs. 0.537% at 10 weeks of
HFD; n=11 for each, P<0.05) (Figure 1F and Supplementary figure VI). Consistent with
this, BM cells (BMCs) from SR-BI−/− mice on HFD contained significantly greater numbers
of hematopoietic colonies forming cells (CFCs) compared with BMCs from WT mice on
HFD (n=8, Figure 1G). In addition, when LSK cells were isolated from mice on HFD and
cultured in vitro, SR-BI−/− LSK cells produced more F4/80+ macrophages than SR-BI+/+
LSK cells (n=7, Figure 1H). Finally, the frequency of LSK cells in the spleen and peripheral
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blood SR-BI−/− mice fed on HFD was significantly higher than in WT mice of HFD (n=4–8,
Figure 1I).
Transplanted SR-BI−/− BM caused enhanced atherosclerotic plaques formation, wherein
grafted cells could be detected
To further demonstrate the increased frequency of HSPC cells in BM of WT and SR-BI−/−
mice on chow diet, we performed limiting dilution competitive repopulation studies.
CD45.2+ WT or SR-BI−/− BM cells were mixed with CD45.1 BM cells at ratios of 1:3, or
1:1 or 3:1, and injected in irradiated CD45.1 recipients. SR-BI−/− CD45.2 chimerism at 4
and 16 weeks after transplantation was significantly higher, consistent with increased
frequency of progenitors and HSPCs in SR-BI−/− murine BM (n=4–6, Figure 2A).
We next wished to determine if SR-BI deficient HSC/HSPC play a role in atherosclerotic
plaque development under HFD conditions. To address this question, we grafted CD45.2
BM cells of SR-BI+/+ or SR-BI−/− mice mixed with equal numbers of CD45.1 BM cells in
irradiated LDLr−/− recipients. After transplantation, recipients were fed on chow diet for the
first 2 months and then switched to HFD for another 2 months. Consistent with the limiting
dilution analysis, higher chimerism of SR-BI−/− CD45.2 cells was observed at 4 and 16
weeks (n=6–10, Figure 2B). Moreover, after 16 weeks of BMT, significantly greater
numbers of CD45.2+ granulocytes and monocytes were observed in recipients transplanted
with SR-BI−/− than WT BM cells (n=6–10, Figure 2, C and D). We also found accelerated
atherosclerosis in the aortic roots of LDLr−/− recipients transplanted with SR-BI−/− BM cells
compared to that WT BM cells (n=6–8, Figure 3, E and F). To further explore the
contribution of SR-BI−/−- and SR-BI+/+- derived inflammatory cells to plaque formation,
cryosections were stained with biotin-CD45.2 and rat anti-mouse CD45 and then
streptavidin 555 and goat anti-rat Alexa 488. The fraction of CD45.2 cells among the CD45+
cells in the plaques was 1.2- fold higher in recipients transplanted with SR-BI−/− BM cells,
compared to those transplanted with WT BMCs (n=6–7, Figure 4, G-H and supplementary
figure III).
Infusion of lipid free human apoA-I inhibited HFD-induced HSPC proliferation, Akt
phosphorylation and plaque progression in LDLr−/− apoA-I−/− mice but had no effect on
SR-BI−/− mice
To determine whether the increased HSPC frequency in SR-BI−/− mice on HFD was due to
enhanced HSPC proliferation, BrdU was injected i.p. into mice 12 hours before sacrifice and
BM cells were stained with anti-LSK and anti-BrdU FITC Abs as described before.3 The
percentage of BrdU incorporating LSK cells among LSK population was 12% in WT mice
on HFD but increased to 18% to SR-BI−/− mice on HFD (SR-BI+/+: 12.2 ± 3.32% ; SR-
BI−/−: 18.6 ± 4.33 ; n=6 for each, P <0.05) (Figure 3A). Apart from enhanced HSPC
proliferation, FACS data also demonstrated an increased percentage of pAkt+ LSK cells in
SR-BI−/− mice on HFD compared to WT mice (pAkt+ LSK%: 15.5 ± 5.00% v.s 9.2 ± 3.76;
n=8 for each, P < 0.05) (Figure 3B). To further assess the pAkt status in HSPC, LSK cells
were sorted from BM or SR-BI+/+ and SR-B−/− mice on HFD. After four days of culture in
SFEM supplemented with stem cell factor (SCF) and thrombopoietin (TPO), pAkt
expression in LSK cells was measured by ELISA (n=11 for each, Figure 3C).
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To further explore if SR-BI was required for the HDL-mediated regulation of HSPC, SR-
BI−/− and WT mice were placed on HFD for 11 weeks and 500 μg lipid free human apoA-I
or saline was injected i.p. into mice twice per week for 3 weeks. In parallel, LDLr−/− apoA-
I−/− mice (DKO) mice on HFD for 9 weeks were injected for the last three weeks with saline
or apoA-I twice weekly for 3 weeks. Mice with deficiency of LDLr and apoA-I developed
hypercholesterolemia and accelerated atherosclerosis when fed on atherogenic diet.22 In
addition, SR-BI is expressed in DKO mice. Thus, performing apoA-I infusion on DKO and
SR-BI−/− mice would allow us to investigate the effect of SR-BI on cells. Consistent with
previous reports,22 apoA-I did not alter cholesterol levels in the blood (data not shown).
However, apoA-I infusion reduced plaque size in DKO mice (45985 ± 18951.1 μm2 vs.
74878 ± 25510.1 μm2, n=6–9, P<0.05) (Figure 3, D and supplementary figure IV).22 We
found a 1.6- fold reduction in LSK frequency in DKO mice injected with apoA-I compared
to saline (n=6–7, Figure 3E). Moreover, the percentage of BrdU+ LSK cells in the whole
LSK population was 37% decreased in DKO mice with apoA-I injection, compared with
saline group (n=6–7, Figure 3F). In addition, we also found a 39% reduction in pAkt
positive LSK cells in mice that received apoA-I infusion compared to control (n=6–7, Figure
3G). Interestingly, apoA-I infusion also reversed the increased ROS content in LSK cells of
DKO mice on HFD (% ROShigh LSK cells in LSK population: 33.5 ± 4.50 vs. 23.4 ± 5.78;
P < 0.05; n=5–6, Figure 4H). In contrast to DKO mice, apoA-I infusion had no effect on
plaque size, LSK cell proliferation or Akt phosphorylation of HSPC in SR-BI−/− mice on
HFD (n=4–7, Figure 3, D–H). To further investigate whether regulation of apoA-I on HSPC
requires SR-BI, LSK cells were obtained from SR-BI+/+ and SR-BI−/− mice for 8-weeks on
chow diet or HFD and transcripts for ABCA1 and β-actin expression measured in LSK cells
by qRT-PCR (Figure 3I). We performed another head to head comparison to confirm that
SR-BI is required for apoA-I-mediated modulation of HSPC number. LDLr−/− recipients
were lethally irradiated and then transplanted with 7 × 106 SR-BI+/+ or SR-BI−/− BMC. Five
days after BM transplantation, the recipients were switched from chow diet to HFD for 8
weeks. Starting from 5th weeks of HFD, 500 μg purified human apoA-I was injected
subcutaneously to all the recipients twice per week for three weeks. Two days after the last
injection, mice were sacrificed and BMC were stained with an Ab cocktail against LSK
cells. FACS data demonstrated that LSK frequency in BMC was lower in LDLr−/− recipients
transplanted with SR-BI+/+ BMC, compared to that of LDLr−/− recipients transplanted with
SR-BI−/− BMC (0.08 ± 0.028% vs. 0.13 ± 0.013%, n=5–7, P<0.05) (Figure 3J). These data
indicate that HDL/apoA-I directly regulates HSPC frequency, proliferation, and ROS
production, all of which is mediated via HDL receptor, SR-BI.
Inhibition of Akt and p38MAPK phosphorylation maintained HSPC quiescence in SR-BI−/−
mice on HFD
As mentioned earlier, p38MAPK phosphorylation is an important mediator of HSPC
differentiation. To evaluate whether p38MAPK phosphorylation was involved in the
regulation of HSPC by HDL and whether apoA-I infusion had any impact on p38MAPK
phosphorylation, SR-BI+/+ and SR-BI−/− mice were fed on HFD and received saline or
apoA-I infusion as described above. BMCs of SR-BI+/+ and SR-BI−/− mice were stained
with antibodies against LSK markers and phospho-p38MAPK. FACS data demonstrated that
the percentage of phospho-p38MAPK+ LSK cells was 1.7- fold higher in SR-BI−/− mice
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compared to SR-BI+/+ mice (15.2 ± 4.01% vs. 8.8 ± 2.37%, n=8 for each, P < 0.01).
Nevertheless, apoA-I infusion did not affect p38MAPK phosphorylation in LSK cells
(Figure 4A) or in LSK cells of DKO mice (data not shown).
To further assess the possible roles of pAkt and phospho-p38MAPK in the aberrant behavior
of LSK cells from SR-BI−/− mice, LSK cells from SR-BI−/− and WT mice were selected by
FACS and cultured in SFEM with stem cell factor, thrombopoietin and IL-3 in the presence
or absence of inhibitors against pAkt and phopho-p38MAPK. On day 5 cell numbers were
enumerated. LSK expansion was determined by comparing cell number with or without
inhibition. As shown in Figure 6B, compared with LSK cells without inhibition, addition of
phospho-p38MAPK inhibitor SB203580 led to 46% and 28% reduction of LSK expansion
in cells from WT mice on HFD and cells from SR-BI−/− mice on chow diet. However,
phospho-p38MAPK inhibitor further inhibited LSK expansion in SR-BI−/− cells on HFD
(n=5–6, Figure 4B). Likewise, pAkt inhibition LY 294002 resulted in 60% and 64%
decrease in LSK cells in cells from WT mice on HFD and cells from SR-BI−/− mice chow
diet, respectively, compared to control. Again, addition of LY 294002 further reduced LSK
expansion in SR-BI−/− cells from HFD (n=5–6, Figure 4C).
Inhibition of ROS production limited SR-BI−/− HSPC expansion induced by HFD
To further determine if the increased ROS levels found in LDLr−/− apoA-I−/− mice on HFD,
could also be linked to the SR-B1 receptor, N-acetyl-L-cysteine (NAC) (1 mg/kg daily) was
injected in SR-BI+/+ and SR-BI−/− mice placed on HFD at the age of 8 weeks for 12
weeks.23 NAC administration did not alter total cholesterol (n=3–7, Figure 5A) and
lipoprotein profiles (data not shown). NAC-treated mice developed body weight loss
compared with saline treated mice (data not shown). However, plasma levels of Serum
Amyloid A was not different among the groups, indicating that NAC injection did not
induce systemic inflammation (SR-BI+/+ mice: 160 ± 13.7 μg/ml on saline group vs. 157 ±
48.7 μg/ml on NAC group; SR-BI−/− mice: 173 ± 9.4 μg/ml vs. 160 ± 57.7 μg/ml on NAC
group). Beside it reversed HFD-induced leukocytosis (n=5–8, Figure 5B), NAC treatment
led to a significantly decreased frequency of LT-HSC, LSK cells and GMP in the BM of
SR-BI−/− mice on HFD (n=7–11, Figure 5, C–E). Furthermore, NAC injection significantly
reduced plaque size 3.8- fold in SR-BI−/− mice on HFD, compared to HFD-fed SR-BI−/−
mice with saline injection (SR-BI+/+ on HFD: 2112 ± 849.4 μm2 ; SR-BI+/+ on HFD and
NAC injection: 1643 ± 1096.5 μm2; SR-BI−/− on HFD: 17237 ± 12131.6 μm2; SR-BI−/− on
HFD and NAC treatment: 5691 ± 3538.9 μm2; n=6–11, Figure 5F and supplementary figure
V).
HDL negatively regulated HSPC frequency and white blood cell count in PB of human
subjects
To investigate if the effect of HDL on mouse HSC and HSPC is also found in human, we
studied the correlation between HDL and WBC level in patients (n=37) with coronary heart
disease. To avoid the influence of acute infection, individuals with WBC counts of > 10,000
cells/μl or neutrophil frequency above 75% were excluded from the study. The basic
characterization of these patients is shown in table 2. Spearman analysis demonstrated a
negative correlation between HDL levels and total WBC count in PB (P<0.05, r=−0.3,
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n=37) (Figure 6A) as well as neutrophils (P<0.05, r=−0.4, n=37) (Figure 6B). As we
observed that females had higher HDL-C than males (HDL-C: 1.07 ± 0.050 vs. 0.92 ±
0.040, P<0.05), Multilogistic Regression Analysis was performed to further investigate the
association between HDL and WBC count by taking age and sex as co-variates. When
taking these variables into account, HDL-C remained negatively correlated with WBC count
in these patients (P=0.02). Consistent with previous reports,24, 25 patients received Statins
treatment had higher HDL-C. Both Statins and aspirin treatments did not affect WBC count.
Next, we measured HSPC (Lin-CD34+CD38-CD45RA−/low) in the blood of patients with
low and high levels of HDL. The percentage of HSPC in mononuclear cells in peripheral
blood (PBMC) was 0.025% in the patients with low HDL and 0.014% in patients with
normal HDL (Figure 6, C and D and Supplementary figure VI, n=6–11, P < 0.05). We could
also detect SR-BI expression on human HSPC (n=6, Figure 7E). Hence, as in mouse, in
humans HDL levels appear to be correlated with leukocytosis and presence of higher
numbers of HSPC, that also express the HDL receptor SR-BI, in the blood.
Discussion
Accumulated studies have described the anti-atherosclerotic properties of HDL. Beside
reverse cholesterol transport, HDL promotes endothelium repair to maintain endothelium
integrity and inhibits inflammatory cell infiltration to lesion site.26–29 Most of the beneficial
regulation of HDL is mediated through HDL receptor Abca1, Abcg1 and SR-BI.26, 30–32
Apart from that, SR-BI also plays a major role in the clearance of lipopolysaccharide.33
Recently, others and we reported that HDL suppresses HSPC proliferation, resulting in the
inhibition of leukocytosis and atherosclerosis progression.2, 3, 34 Although we described that
SR-BI is expressed on murine HSPC and that HSPC proliferation is inhibited by apoA-I
infusion,3 whether and how SR-BI is involved in the HDL-mediated regulation of HSPC is
unknown. Here we demonstrate that SR-BI is required for the HDL-mediated regulation of
HSPC quiescence, proliferation and differentiation. The signaling pathways underlying the
regulation of HDL on HSPC are Akt phosphorylation, p38 MAPK phosphorylation and ROS
production downstream of SR-BI.
Hypercholesterolemia stimulates monocyte and HSPC proliferation,2, 3, 35 leading to
leukocytosis, monocytosis and atherosclerosis development. Like macrophages, HSPC
express Abca1, Abcg1 and apoE,2, 34 all of which regulate intracellular cholesterol
homeostasis. Both Abca1/Abcg1 and apoE deficiency impair cholesterol efflux, leading to
cholesterol accumulation in lipid rafts in cell membranes. This change of lipid rafts leads to
increased localization of receptors such as IL-3/GM-CSF receptor on the surface; and
modulates phosphorylation cascades originating from membrane-bound proteins.2, 34 As a
result, proliferation and differentiation of HSPC is triggered, resulting in an enhanced white
blood cell pool in the PB. In this study, we identified a role for SR-BI in HSPC quiescence
vs. proliferation in response to apoA-I. The phenotype of SR-BI−/− mice shared some
features in common with Abca1−/−Abcg1−/− and apoE−/− mice in the aspect of HSPC
proliferation, leukocytosis and accelerated atherosclerosis induced by hypercholesterolemia.
Based on the nature of SR-BI in cholesterol transport and our findings, we assumed that
both impaired cholesterol homeostasis and activated phosphorylation cascades may be
involved in SR-BI−/− HSPC proliferation. This assumption is supported by several lines of
Gao et al. Page 8
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
observations: (1) higher HSPC frequency and more HSPC proliferation in SR-BI−/− on HFD
than SR-BI+/+ on HFD; (2) apoA-I infusion prohibited Akt phosphorylation in HSPC of
DKO mice on HFD but not in SR-BI−/− on HFD, and correspondingly, (3) infusion of
human apoA-I reduced HSPC frequency and inhibited HSPC proliferation in DKO mice on
HFD, but not in SR-BI−/− mice on HFD; (4) in vitro inhibition of Akt phosphorylation
reduced SR-BI−/− LSK expansion more than that of SR-BI+/+ LSK cells when both were
isolated from HFD feeding mice. Apart from higher pAkt in HSPC of SR-BI−/− mice on
HFD, we also detected more phospho-p38MAPK on HSPC in these mice. Addition of
phospho-p38MAPK inhibitor restrained more SR-BI−/− LSK expansion than SR-BI+/+ LSK
when they were isolated from mice on HFD. Thus, both Akt phosphorylation and p38MAPK
phosphorylation may contribute to HSPC activation and proliferation, which are
downstream of SR-BI. However, to fully prove this, in vivo Akt and p38MAPK inhibition
studies will be needed, which can technically not be performed. Apart from these findings,
we noticed that neither apoA-I infusion nor NAC injection altered cholesterol level in the
blood of these mice despite they suppressed HSPC proliferation. These data suggest that
intracellular signaling pathways may contribute more substantially than lipid raft to the
determination of HSPC cell fate.
As described earlier, HSPC reside in low oxygen BM niche and have low intracellular level
of ROS, which help maintain their quiescence and self-renewal capacity.6, 13 In Ataxia
telangiectasia (A-T) mutated (Atm−/−) mice, Atm−/− HSPC cycle more active than Atm+/+
HSPC, resulting in HSPC exhaustion and loss of BM reconstitution capacity.11 In Mdm2−/−
mice, due to Mdm2 deficiency, p53 expression was up-regulated and ROS production was
increased in HSPC, leading to enhanced cell death.36 Prohibition of ROS production by
NAC treatment rescued ROS-induced HSPC defects in Atm−/− and Mdm2−/− mice.11, 36 In
parallel, the adverse effects of ROS in atherosclerosis development have been extensively
studied. All the findings consistently delineated that enhanced ROS production induced
endothelial cell death and dysfunction,37, 38 plaque instability by ROS-induced activation of
matrix metalloproteinases,39 and inflammation.40, 41 In this study, we investigated the
physiological and pathological meaning of ROS in the context of HSPC, HDL, SR-BI and
atherosclerosis. We demonstrate that hypercholesterolemia stimulated HSPC proliferation
and enhanced ROS production, which was associated with plaque development in SR-BI−/−
mice. ApoA-I infusion attenuated HFD-induced ROS production, HSPC expansion and
atherosclerosis progression in DKO mice. Similarly, NAC treatment reversed HFD-induced
HSPC proliferation and leukocytosis and inhibited atherosclerosis progression in SR-BI−/−
mice. Although the contribution of pAkt and phospho-p38MAPK on ROS production in
HSPC is yet to be defined, suppression of ROS production in HSPC seemed to have a
beneficial role in atherosclerosis. To our knowledge, this is the first study demonstrating a
link between hypercholesterolemia, ROS, HSPC activation and atherosclerosis.
By FACS, SR-BI was detected on human and murine HSPC. Furthermore, the number of
white blood cells and HSPC in blood was intimately and negatively associated with HDL
level in individuals. Taken the mice findings together, we speculated that HDL could
regulate human HSPC via SR-BI. Perspective, it would be very interesting to investigate the
relationship of HSPC and atherosclerosis in patients with SR-BI mutation and deficiency.
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Overall, in line with the previous reports, this study confirmed the link between HSPC
proliferation, leukocytosis and atherosclerosis progression. In addition, we demonstrated
that the HDL receptor, SR-BI is expressed on HSPC as well as Abca1 and Abcg1. SR-BI
could play a critical role in the control of HSPC proliferation and differentiation, therefore,
limiting HFD-induced leukocytosis in blood, inflammatory cell infiltration in plaque and
plaque progression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Nonstandard abbreviations
HDL high density lipoprotein
apoA-I apolipoprotein A-I
HSPC hematopoietic stem/progenitor cells
PB peripheral blood
LSK cells Lin- Sca-1+ cKit+ cells
SR-BI scavenger receptor type BI
LT-HSC long term hematopoietic stem cells
ROS reactive oxygen species
BM bone marrow
WBC white blood cells
LDL low density lipoporotein
LDLr−/− low density lipoprotein receptor knockout
GMP granulocyte monocyte progenitors
HFD high fat diet
WT wide type
Gao et al. Page 10
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
DKO LDLr−/− apoA-I−/−
NAC N-acetylcysteine
pAkt phospho Akt
PBMC mononuclear cells in peripheral blood
Atm Ataxia telangiectasia (A-T) mutated
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Significance
The athero-protective properties of HDL and SR-BI have been shown in multiple cell
types including hepatocytes, macrophages, endothelial cells and endothelial progenitors.
Hereby, we demonstrated that HDL suppresses hematopoietic stem/progenitor cell
(HSPC) proliferation that is mediated via SR-BI. In addition, we highlighted the link
between HDL-mediated inhibition of reactive oxygen species (ROS) content in HSPC,
reduced HSPC activation and leukocytosis, and attenuation of atherosclerosis
progression, all of which is SR-BI-dependent. Providing that inflammatory cells in
atherosclerotic plaque are exclusively derived from HSPC, these findings not only enrich
our knowledge of atherosclerosis in the context of HDL, SR-BI and HSPC but also shed
lights on therapeutic interventions of atherosclerosis.
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Figure 1. High fat diet promoted leukocytosis, monocytosis in PB and HSPC expansion in BM,
which was associated with atherosclerosis development
SR-BI+/+ and SR-BI−/− mice were placed on chow or high fat diet at the age of 3 months,
onward for 8 or 10 weeks. Peripheral white blood cell and monocyte counts were shown in
A and B, respectively. n=9–21. (C) To assess the components of monocytes in PB, blood
cells of mice on high fat diet were stained with anti-CD11b PE and anti-F4/80 APC-Cy7 and
macrophages were quantified by FACS. (D) BMCs were stained with anti-CD150 FITC,
anti-CD48 PE and LSK markers and LT-HSC (CD150+ CD48− LSK cells) was quantified
by FACS. (E) Quantification of LSK frequency in mice on chow and HFD. (F)
Quantification of GMP (CD34+ FcR+ Lin− cKit+ Sca-1 cells) in BMCs. n=8–10. (G) BMCS
(1×104) from SR-BI+/+ and SR-BI−/− mice on HFD were seeded on methylcellulose and
hematopoietic colonies were numerated at day 10–14. (H) LSK cells of SR-BI+/+ and SR-
BI−/− mice on HFD were sorted out by FACS and cultured in vitro for 10 days. Cells were
stained with anti-CD11b PE and anti-F4/80 APC-Cy7 to study macrophage production. (I)
Quantification of LSK frequency in splenocytes and PBMC. To achieve a comparable
analysis of HSPC frequency, 8 of 10 SR-BI+/+ mice on chow diet were females and 8 of 10
SR-BI−/− mice on chow diet were females. The mice on HFD were all males.
Gao et al. Page 15
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. The effect of SR-BI deficiency on BM reconstitution and plaque progression in
hypercholesterolemic mice
(A) To compare the LSK frequency in mice on chow diet, SR-BI+/+ or SR-BI−/− CD45.2
BMCs were mixed with CD45.1 BMCs at ratios of 3:1, 1:1 and 1:3 and injected in irradiated
CD45.1 recipients. (B) Equal numbers of SR-BI+/+ or SR-BI−/− BMCs were mixed with
CD45.1 BMCs and injected in irradiated LDLr−/− recipients. Following BM transplantation,
the recipients were first fed on chow diet for 8 weeks and then switched to high fat diet
(HFD) for another 8 weeks. Blood cells were stained with anti-mouse CD45.1 and anti-
mouse CD45.2 to assess chimerism by FACS. (C–D) The contribution of SR-BI+/+ and SR-
BI−/− HSPC to monocytes and granulocytes is shown in Figure 2C and 2D, respectively. (E)
Quantification of atheroma in aortic roots of LDLr−/− mice transplanted with SR-BI+/+ or
SR-BI−/− BMCs. (F) Representative H&E pictures of LDLr−/− mice received SR-BI+/+ or
SR-BI−/− BMCs. Scale bar: 200 μm. (G) Cryosections were stained with rat anti-mouse
CD45 and biotin CD45.2 antibodies overnight and then goat anti-rat Alexa 488 and
Streptavidin 555. CD45.1− and CD45.2− derived cells were quantified. Data are expressed
as the percentage of CD45.2+CD45+ cells in CD45+ cells. (H) Representative image
demonstrating CD45 cells in the plaques. CD45.1-derived cells are indicated by white
arrows, whereas CD45.2− derived cells are indicated by yellow arrows. Scale bar: 20 μm.
Male donors and recipients were used in both BM transplantation experiments.
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Figure 3. Human apoA-I infusion inhibited HSPC proliferation, reduced ROS production in
HSPC and reversed plaque progression
To quantify the proliferative status of HSPC in vivo, BrdU was injected in mice. BrdU
positive LSK cells were quantified by FACS (Figure 4A). Akt phosphorylation (pAkt) in
LSK cells was studied by staining BMCs with PE-conjugated anti-pAkt and LSK antibodies
for FACS (B) and pAkt level in ex vivo expanded LSK cells were confirmed by ELISA (C).
(D) Plaque size in aortic roots of SR-BI−/− and LDLr−/− apoA-I−/− (double knock-out, DKO)
mice that were placed on high fat diet (HFD) and received saline or human apoA-I injection.
Quantification of LSK frequency (E) and LSK proliferation (F) in BMC of SR-BI−/− and
DKO mice that were treated with HFD and injection of saline or apoA-I. (G) The percentage
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of pAkt+ LSK cells in the entire LSK cell population in mice was measured by FACS. (H)
BMCs were stained with LSK antibodies and then incubated with DCF-DA. The percentage
of ROShigh LSK cells in the LSK population was quantified by FACS. Only male SR-BI+/+,
SR-BI−/− and LDLr−/−apoA-I−/− mice were used in the apoA-I infusion experiments. (I)
ABCA1 expression in LSK cells of male SR-BI+/+ and SR-BI−/− mice on chow and HFD.
n=3–6. (J) Following apoA-I injection, LSK frequency in LDLr−/− recipients transplanted
with SR-BI+/+ or SR-BI−/− BMC. n=5–7. 6 male LDLr−/− and 6 LDLr−/− female recipients
were used in the BM transplantation experiment.
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Figure 4. The roles of p38MAPK and Akt phosphorylation on LSK quiescence
SR-BI+/+ and SR-BI−/− mice were fed on high fat diet (HFD) for 8 weeks and then injected
with saline or apoA-I while keeping the mice on HFD. (A) BMCs were stained with PE-
conjugated antibody against phospho-p38MAPK and LSK antibodies. The percentage of
phospho-p38MAPK+ LSK cells in the LSK population was obtained by FACS. (B–C) LSK
cells from SR-BI+/+ on HFD, SR-BI−/− on chow and HFD mice were isolated by FACS and
cultured in vitro in the presence or absence of the phospho-p38MAPK inhibitor SB 203580
(B) and pAkt inhibitor Ly 204950 (C). Four days after culture, the cell number was
enumerated. Data are expressed as fold reduction when compared to cells cultured without
inhibitor. Male SR-BI+/+, SR-BI−/− mice were used in the apoA-I infusion experiments in
vivo and HSPC expansion in vitro.
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Figure 5. The effect of ROS inhibition on HSPC frequency and plaque progression
SR-BI+/+ and SR-BI−/− mice were fed on high fat diet (HFD), without or with N-acetyl-L-
cysteine (NAC) injection for 12 weeks. Total cholesterol is shown in A. White blood cell
count is displayed in B. BMCs were stained with anti-CD150 FITC, anti-CD48 PE and LSK
antibodies to quantify the percentage of LSK cells (C) and CD150+CD48-LSK cells (D) in
BMC. (E) Quantification of GMP frequency in BMCs of mice on HFD with or without
NAC treatment. (F) Plaque size in aortic roots of mice on HFD with or without NAC
treatment. n=7–11 per group. In the entire NAC injection experiments, 9 of 13 SR-BI+/+
mice were females and 10 of 18 SR-BI−/− mice were females.
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Figure 6. Negative correlation between HDL, WBC and HSPC in PB of human subjects
In patients with coronary heart disease the correlation between HDL level and WBC and
neutrophil count was assessed. Patients whose WBC count exceeded 10 ×109/l or neutrophil
frequency exceeding 75% were excluded to avoid the influence of acute inflammation. (A)
Correlation between HDL and WBC count. r=−0.339, p=0.04, n=37. (B) Correlation
between HDL and neutrophil count. r=−0.356, p=0.031, n=37. (C) When PBMC were
stained with anti-CD34, CD38, CD45a and lineage antibodies, and the number of
CD34+CD38-CD45A-Lin- cells in PBMC of patients with low (<1.04 mmol/l) and normal
HDL (>1.04 mmol/l) was analyzed. (D) Representative dot plots demonstrate CD34+
CD45RA− HSPC when gated on Lin− CD38− cells. HSPC frequency is indicated in the left
corner. (E) PBMC were stained with rabbit anti-mouse SR-BI and then goat anti-rabbit
Alexa 488 and anti-CD34, CD38, and lineage Abs, SR-BI expression was detected on
Gao et al. Page 21
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
CD34+CD38-Lin- cells by FACS. The representative dot plots showed SR-BI expression in
CD34+ cells when gated on Lin− and CD38− cells.
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Table 1
Basic characteristics of patients enrolled in the correlation and HSPC studies
Patients diagnosed as coronary heart disease were enrolled in the study. Their disease history and medical
measurements are characterized below.
Parameters HDL < 1.04 mmol/l HDL > 1.04 mmol/l p value
number 22 15
Age (year) 64 ± 3.0 60 ± 2.7 0.33
BMI (kg/m2) 24.2 ± 1.23 23.0 ± 0.79 0.44
Systolic pressure (mmHg) 124.2 ± 4.34 125.9 ± 2.22 0.75
Diastolic pressure (mmHg) 78.33 ± 3.66 75 ± 3.59 0.52
White blood cells (109/l) 7.6 ± 0.28 6.2 ± 0.33 0.03*
Neutrophils (109/l) 4.9 ± 0.27 3.7 ± 0.28 0.004*
Red blood cells 4.2 ± 0.18 4.4 ± 0.18 0.43
Glucose (mmol/l) 9.4 ± 1.12 9.5 ± 1.01 0.97
Platelet 227 ± 15.4 211 ± 15.6 0.93
Total cholesterol (mmol/l) 4.54 ± 0.219 5.3 ± 0.315 0.046*
LDL (mmol/l) 2.85 ± 0.184 3.74 ± 0.323 0.014*
Total tryglyceride (mmol/l) 2.12 ± 0.271 1.69 ± 0.284 0.30
*
compared with patients with low HDL.
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